Facebook Instagram Linkedin Youtube
Home Search

Cereno scientific - search results

If you're not happy with the results, please do another search
Cereno OMPD

Cereno comments on EU orphan designation for CS1

Saniona siktar på nya kliniska data och ett första marknadsgodkännande

Saniona aiming for new clinical data and first market approval

Cereno Scientific Q2 report 2024

Cereno’s CEO: “very excited for topline readout!”

Continued focus on new licensing deals for CombiGene

Continued focus on new licensing deals for CombiGene

Peter Hovstadius

Lipum recruits new CMO: “I have been following their research for...

BioStock: Alzinova’s CEO - “we are a top actor in the Alzheimer’s field”

Alzinova’s CEO: “We are a top actor in the Alzheimer’s field”

Phase Holographic Imaging to list in the US

PHI aims for US listing

Cereno vdkommentar

Cereno’s CEO comments on progress with CS1 and CS014

Åsa Magnusson

Lipum strengthens the board with commercial expertise

Alligator Fas II-data

“Unprecedented” phase II data for Alligator in pancreatic cancer

BioInvent immunotherapy 2.0

Top oncologist underscores BioInvent’s potential for “Immunotherapy 2.0”

Oncoinvent

Fast Track designation facilitates development of Oncoinvent’s Radspherin

Cereno granted approval to initiate Phase I trial with CS014

Cereno’s CEO: “CS014 adds potential for cardiovascular disease patients”

PHI grows its network of collaborations

PHI grows its network of collaborations

Elicera teams up with China Medical University for cancer study

Elicera teams up with China Medical University for cancer study

Biosergen towards first-in-patient trial with antifungal therapy

Biosergen towards first-in-patient trial with antifungal therapy

Alligator’s mitazalimab data published in The Lancet Oncology

Alligator’s mitazalimab data published in The Lancet Oncology

Cirasight works on the financing

Curasight committed to progressing pipeline

Dicot has completed recruitement

She is CombiGene’s new CSO

Kiarash Farr

Prolight Diagnostics strengthens board with experienced business developer

Full focus on financing and new CEO for Arcede

Full focus on financing and new CEO for Arcede

CLS

CLS launches in France

Lipum

Flerie Invest continues to support Lipum

Enzymatica

MDR certification was Enzymatica’s highlight in Q1

Oncoinvent

Oncoinvent strengthens board and cash position

Medivir continues to accelerate development with fostrox

Medivir continues to accelerate development with fostrox

BiBB’s CEO: “Patient cases fortify our confidence in EndoDrill”

BiBB’s CEO: “Patient cases fortify our confidence in EndoDrill”

Abliva’s mission to become mitochondrial medicine powerhouse

Abliva’s mission to become mitochondrial medicine powerhouse

Chordate

Chordate comments on Q4 and case report

Cyxone comments on the clinical collaboration in the UK

Cyxone comments on the clinical collaboration in the UK

Per Norlén, CEO WntResearch

WntResearch’s new CEO comments on his first month in the position

SynAct

Synact’s new CEO: “I’m hitting the ground running”

Alligators vd om den aktuella utvecklingen och företrädesemissionen

Alligator’s CEO on current development and the rights issue

Enzymatica

Enzymatica comments on MDR certification for ColdZyme

CLS

Publication in Journal of Neurosurgery demonstrates the benefits of CLS’ technology

Cline cartilage damage

Scientific Advisor on the potential of Cline’s cell therapy for cartilage...

Dicot has completed recruitement

Dicot’s phase I study fully recruited

Cereno’s new Chief Medical Officer and Head of R&D comments on progress with CS1

Cereno’s new CMO and Head of R&D comments on progress with...

Scandions vd kommenterar det positiva patentbeskedet i USA

Ytterligare tumörreduktion i Scandions cancerstudie

Tine Kold Olesen, CEO Biosergen

Biosergen CEO: “Positive data give us a strong value proposition”

Cyxones CEO Carl-Magnus Högerkorp

Cyxone’s CEO gives a status update

Comments from Orphazyme on the investment in CombiGene

Comments from Orphazyme on the investment in CombiGene

Aptahem comments on the publication in Cells

Aptahem comments on the publication in Cells

Steve Ross

Prolight Diagnostics’ CTO highlights the potential of the Psyros system

Enzymatica

Enzymatica’s partners await MDR certification and study results

Prolight Diagnostics goals

Prolight Diagnostics CEO: “We deliver on all goals”

Ultimovacs receives Orphan Drug Designation from EMA

Ultimovacs receives Orphan Drug Designation from EMA

Alligator prepares for phase III with CD40 agonist

Alligator prepares for phase III with CD40 agonist

Curasight accelerates with rights issue

Curasight to accelerate therapeutic strategy by DKK 51.2 million capital raise

Spago Nanomedical_2024 Momentum

2023 springboard for Spago’s radionuclide cancer therapy

Sten R Sörensen, CEO CerenoScientific

Cereno’s CEO on being granted “Compassionate Use”

Evaxion_CancerVaccine_Concept

Evaxion to develop novel precision cancer vaccine concept

Roche acquisition

Prolight‘s CEO: “Roche’s acquisition highlights interest in Point-of-Care” 

Pia Baumann, CMO Medivir

Medivirs CMO: “Our new clinical data are very encouraging”

Nasdaq introduces auction trading

Nasdaq introduces auction trading on First North

Dendritic

Cyxone identifies target protein for rabeximod 

Stayble

Stayble’s CEO: “We are looking forward to new study results in...

Alzinova's CMO wants to bring forward a vaccine against Alzheimer's

Alzinova’s CMO wants to bring forward a vaccine against Alzheimer’s

Arcede Pharma prepareds for phase I

Arcede aims for clinic with TO1

Chordate

Chordate continues its marketing activities and exit strategy

123...8Page 1 of 8
© BioStock 2024